Your browser doesn't support javascript.
loading
Fluorouracil sustained release agent in the treatment of advanced gastric cancer / 中国组织工程研究
Article de Zh | WPRIM | ID: wpr-437501
Bibliothèque responsable: WPRO
ABSTRACT
BACKGROUND:Fluorouracil sustained-release agent is a commonly used anti-cancer sustained-release drug, which has a good anti-tumor effect. OBJECTIVE:To explore the effect of fluorouracil sustained-release agent in the treatment of gastric cancer. METHODS:Literatures concerning the effect of fluorouracil sustained-release agent in the treatment of gastric cancer were retrieved and analyzed. In the paper, we investigated the preventive effect of fluorouracil sustained-release agent against tumor recurrence and metastasis after radical resection, and fol owed up the patients who underwent clinical peritoneal implantation of fluorouracil sustained-release agent. We could determine the effect of fluorouracil sustained-release agent in the treatment of advanced gastric cancer by observing the patient’s symptoms and signs, expression of tumor markers, tumor size and survival rate. RESULTS AND CONCLUSION:After combination therapy of fluorouracil sustained-release agent and arterial infusion chemotherapy adjuvant therapy, the patient’s symptoms and tumor resection rate were significantly improved. The levels of CEA, CA19-9, CA72-4 in the serum of patients significantly reduced, while the apoptosis and necrosis of tumor cells significantly increased. Fluorouracil sustained-release agent could also reduce tumor metastasis and local recurrence, and improve patient survival.
Mots clés
Texte intégral: 1 Indice: WPRIM langue: Zh Texte intégral: Chinese Journal of Tissue Engineering Research Année: 2013 Type: Article
Texte intégral: 1 Indice: WPRIM langue: Zh Texte intégral: Chinese Journal of Tissue Engineering Research Année: 2013 Type: Article